APA (7th ed.) Citation

JD, Z., CG, R., BL, S., A, O., & Z, T. (2022). Cabotegravir: A novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection. Drugs of today (Barcelona, Spain : 1998), 58(12), 555. https://doi.org/10.1358/dot.2022.58.12.3448340

Chicago Style (17th ed.) Citation

JD, Zeuli, Rivera CG, Smith BL, Otto A, and Temesgen Z. "Cabotegravir: A Novel HIV Integrase Inhibitor Combined with Rilpivirine as the First Long-acting Injectable Program for the Treatment of HIV Infection." Drugs of Today (Barcelona, Spain : 1998) 58, no. 12 (2022): 555. https://doi.org/10.1358/dot.2022.58.12.3448340.

MLA (9th ed.) Citation

JD, Zeuli, et al. "Cabotegravir: A Novel HIV Integrase Inhibitor Combined with Rilpivirine as the First Long-acting Injectable Program for the Treatment of HIV Infection." Drugs of Today (Barcelona, Spain : 1998), vol. 58, no. 12, 2022, p. 555, https://doi.org/10.1358/dot.2022.58.12.3448340.